Roger Greenberg

Professor of Cancer Biology University of Pennsylvania

Seminars

Tuesday 27th January 2026
Uncovering Chromatin Remodeling & ALT Vulnerabilities: Targeting ALC1 and FANCM to Advance Biomarker-Driven Synthetic Lethality
1:15 pm
  • Demonstrating how ALC1 inhibition enhances PARP trapping and PARP inhibitor responses in HR-deficient cancers
  • Establishing FANCM dependency as a therapeutic vulnerability in ALT-positive tumors, unlocking new synthetic lethality opportunities
  • Highlighting biomarker strategies to identify HR-deficient and ALT-driven patients for precision deployment of ALC1 and FANCM–targeted therapies
Roger G